



REVIEW

Open Access



The role of alpha-actinin-4 in human kidney disease

Di Feng¹, Clark DuMontier² and Martin R Pollak^{1*}

Abstract

Mutations in the Alpha-actinin-4 gene (ACTN4) cause a rare form of familial focal segmental glomerulosclerosis in humans. Individuals with kidney disease-associated ACTN4 mutations tend to have mild to moderate proteinuria, with many developing decreased kidney function progressing to end stage kidney disease. All of the disease-causing ACTN4 mutations identified to date are located within the actin-binding domain of the encoded protein, increasing its binding affinity to F-actin and leading to abnormal actin rich cellular aggregates. The identification of ACTN4 mutations as a cause of human kidney disease demonstrates a key cellular pathway by which alterations in cytoskeletal behavior can mediate kidney disease. Here we review the studies relevant to ACTN4 and its role in mediating kidney disease.

Keywords: Focal segmental glomerulosclerosis, Alpha-actinin-4, Kidney, Podocytes, Cytoskeleton protein

Background

Focal segmental glomerulosclerosis (FSGS) is a common histologic pattern of kidney injury, often associated with progressive chronic kidney disease and overt kidney failure. FSGS is defined histologically by sclerosis occurring in a portion of the glomerulus and affecting a subset of glomeruli. While these biopsy features define a pattern of injury, they do not define the underlying etiology [1]. Electron microscopy typically shows fusion of epithelial cell foot processes, or so-called foot process effacement. Common features of FSGS patients include proteinuria, edema, hypertension and hypercholesterolemia.

FSGS is found in about 20–25% of all renal biopsies [2, 3]. However, the incidence and prevalence of FSGS in children may be underestimated [4]. This is because many children with nephrotic syndrome (NS), defined as heavy proteinuria, hypoalbuminemia, and peripheral edema, are generally assumed to have minimal change syndrome and not subjected to renal biopsy. Even when a biopsy is performed, the characteristic lesion necessary for diagnosis might not be captured in the sample. It is

estimated that the incidence of NS in children is between 2 and 4 new cases per 100,000 children per year, with biopsy-confirmed FSGS comprising 15–20% [4, 5]. The prevalence of FSGS continues to increase for unknown reasons [2, 5, 6]. FSGS is seen in approximately 2–5% of cases of end stage renal disease (ESRD) in adults and about 10% in children [7].

A number of etiologies have been associated with FSGS and are often used as the basis for further classification. Broadly, FSGS is divided into primary (idiopathic) and secondary forms. Secondary FSGS is thought to result from a wide range of systemic conditions, including reflex nephropathy, heroin use, decreased renal mass, hypertension, diabetes, obesity, and HIV infection [8, 9]. In comparison with secondary FSGS, primary FSGS is more likely to present with nephrotic-range proteinuria and have a poorer prognosis, with 50% progressing to ESRD over 3–8 years ([9, 10]. For FSGS patients with nephrotic-range proteinuria, the use of corticosteroids is associated with an increased likelihood of a remission [9, 11]. However, steroid resistance can be present in up to 50% of patients, and a prolonged steroid treatment is associated with significant side effects [9]. Therefore, there is great interest in understanding the molecular mechanisms underlying different forms of FSGS and kidney injury. Mutations in several genes are associated with

*Correspondence: mpollak@bidmc.harvard.edu

¹ Division of Nephrology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA

Full list of author information is available at the end of the article

familial forms of FSGS or nephrotic syndrome, including α -actinin-4 (here we use ACTN4 to designate the human gene or protein and Actn4 to designate the mouse gene or protein) [12], inverted formin 2 (INF2) [13], canonical transient receptor potential 6 (TRPC6) [14, 15], nephrin (NPHS1) [16], and podocin (NPHS2) [17]. This review will focus on ACTN4 and its role in mediating human FSGS.

The α -actinins are 100 kD rod shaped proteins that form head-to-tail homodimers [18]. α -Actinin monomers contain three distinct domains: an N-terminal actin binding domain (ABD), four spectrin-like repeats (SRs), and a C-terminal EF hands (calmodulin like domain). There are four human α -actinin (ACTN1-4) family members, encoding closely related actin crosslinking proteins. ACTN2 and ACTN3 (calcium insensitive) show sarcomere-limited expression [19]. The non-muscle cytoskeletal ACTN1 (highly calcium sensitive) and ACTN4 (moderately calcium sensitive), appear to be widely expressed [20, 21]. However, for unclear reasons, the human phenotype associated with ACTN4 mutations is apparent only in the kidney [12]. Additionally, ACTN1 mutations were identified as a cause of congenital macrothrombocytopenia, an inherited disorder showing low platelet counts [22]. ACTN2 mutations have been found in rare families with hypertrophic cardiomyopathy [23]. The ACTN3 R577X variant, leading to absence of ACTN3 protein due to an early stop-codon, is absent in 18% of healthy white individuals [24]. There is no apparent disease phenotype as a result of this variant. However, the homozygous genotype appears with very low frequency in elite sprint athlete [25]. The loss of ACTN3 is associated with reduced skeleton high velocity contraction. Altogether, these studies revealed unique roles of different α -actinin isoforms different tissues.

In addition to bundling F-actin, ACTN4 interacts with various other proteins, consistent with multiple roles in cell function. Some of these studies were conducted either using crude extraction of α -actinin or anti- α -actinin antibodies that are not specific for ACTN4. For example:

1. *Cell adhesion* α -actinins interact directly with β 1-integrin [26, 27], vinculin [28, 29], zyxin [30], kindlin-1 [31] to modulate focal adhesion, and to link the cytoskeleton to the extracellular matrix.
2. *Cell junction* The glomerular slit diaphragm between podocyte foot processes shares many morphologic features with the adherens junction seen in epithelial cells. The glomerular slit diaphragm composes of P-cadherin, α -catenin, β -catenin, γ -catenin, and ZO-1 [32]. α -actinins have been shown to interact directly with α -catenin [33]. Moreover, the slit-diaphragm protein nephrin appears to form a major structural component of the slit diaphragm between adjacent podocytes. ACTN4, together with five other cell junction proteins, including the membrane-associated guanylate kinase inverted 2_synaptic scaffolding molecule (MAGI-2/S-SCAM), IQ motif-containing GTPase activating protein1 (IQGAP1), α II spectrin, and β II spectrin was detected as part of the nephrin multiprotein complex [34]. Therefore, ACTN4 could serve as a linker between F-actin and other adherens junction proteins.
3. *Cell signaling* One of the key signaling molecules phosphatidylinositol 4,5-bisphosphate (PIP2) was shown to bind α -actinin at the plasma membrane. Upon PI3 Kinase (PI3K) activation, PIP2 is converted to phosphatidylinositol 3,4,5-trisphosphate (PIP3), which decreases the association of α -actinin to actin filament within stress fibers, as well as the association rate to integrin within focal adhesions [35, 36]. Moreover, ACTN4 can interact PI3K downstream kinase Akt to mediate cell proliferation [37]. Finally, PIP3 binding ACTNs also increases their susceptibility to calpain-1 and -2-mediated proteolysis [38].
4. *Nuclear transcription activator* ACTN4 was reported to be present in cell nuclei in 1998 [39]. Notably, PI3K inhibition and actin depolymerization both promote nuclear accumulation of ACTN4. Since then, ACTN4 has been reported to be a transcription activator of the estrogen receptor (ER α) [40, 41], the retinoic acid receptor (RAR) [42], the myocyte enhancer factor (MEF) [43, 44], the vitamin D receptor [41], the androgen receptor [45], NF- κ B transcription factors [46], thus potentially regulating transcription activity of multiple genes.

ACTN4 mutations in humans with FSGS

Positional cloning approaches identified three different point mutations in ACTN4 as the cause of FSGS in three unrelated families [12]. These families show autosomal dominant inheritance of disease, with high but incomplete penetrance and variable expressivity. Most of the affected individuals initially presented with low-grade proteinuria mainly in early adulthood with declining kidney function that slowly progressed to ESRD. The K255E, T259I, and S262P mutations identified in these families are all located within the evolutionarily conserved ABD of ACTN4. As assessed by actin filament co-sedimentation assays, all mutations are associated with increased ACTN4 binding affinity to F-actin. ACTN4, but not ACTN1, is expressed at high levels (as detected by western blot) in human kidney. By immunofluorescence staining, it was found that ACTN4 is most prominently distributed in podocytes, with some distribution in other

vasculature in the renal cortex. These findings are consistent with previous reports, suggesting that ACTN4 is highly expressed in podocytes, and with less expression elsewhere within the kidney [47, 48].

Two additional missense mutations in the ABD, W59R and I149del, were subsequently defined as disease-causing based on the following criteria: (1) mutants formed abnormal cellular aggregates with F-actin within the cell; (2) these mutations increased binding affinity of ACTN4 to F-actin, (3) ACTN4 with these mutations cosegregated with affected individuals within families; (4) the mutations occur in evolutionarily-conserved ABD domain [49]. ACTN4 mutations (five total disease-causing mutations including the three previously discovered) accounted for approximately 3.5% of 141 familial FSGS cases screened in this study. The W59R substitution identified in this study was of particular interest as it was a *de novo* mutation not present in the proband's parent. This individual exhibited proteinuria at age 5 and progressed to ESRD within 3 years, much earlier than other families with ACTN4 mutations. In addition, this individual developed recurrent proteinuria and FSGS after transplantation, the only such case reported to date.

Another clinical report documented a germline mosaicism ACTN4 mutation at S262F in the father of two affected siblings [50]. This mutation occurs at the same location as the previously reported heterozygous mutation S262P. Both patients developed FSGS in early childhood (3–4 years old) and rapidly progressed to ESRD. Renal biopsy showed a collapsing variant of FSGS in one affected sibling, a histological subtype of FSGS associated with a poorer prognosis. All of the disease causing ACTN4 mutations and their location in ABD has been summarized in Fig. 1 [51, 52].

Actn4 mouse models

Kos et al. generated Actn4 knockout (Actn4 KO) mice [53]. A significant percentage of homozygous Actn4 KO mice suffer perinatal death. The remaining survivors go on to develop albuminuria and FSGS at about 10 weeks of age. Transmission electron microscopy of these Actn4 KO mice shows podocyte foot-process effacement. There is no clear alteration in podocin, nephrin, or type IV collagen expression in homozygous Actn4 KO mice by immunofluorescence staining. Even though strong expression of both Actn1 and Actn4 are detected in wild type (WT) mouse podocytes, the loss of Actn4 alone leads to a significant renal phenotype, suggesting that Actn4 plays a nonredundant role in the mouse kidney. Additionally, homozygous Actn4 KO mice also show a decrease in the number of podocytes in the glomeruli, and a significant increased number of podocytes shedding in the urine as indicated by the presence of podocyte marker WT-1 protein [54]. Podocytes isolated from homozygous Actn4 KO mice showed decreased phosphorylation of β 1-integrin and weaker integrin-cytoskeleton linkages. Consequently, they also showed decreased attachment in response to shear stress in culture. Altogether, homozygous Actn4 KO mice demonstrated the importance of the expression level of Actn4 in kidney disease. Indeed, Liu et al. reported that decreased expression of ACTN4 could occur in humans with primary glomerulopathies including sporadic FSGS, minimal change disease, and IgA nephropathy [55].

Yao et al. generated Actn4 K256E (a mutation analogous to the FSGS-causing K255E mutation in humans) knock-in (Actn4 KI) mice in an effort to mimic the human phenotype [56]. Homozygous Actn4 KI mice also showed perinatal lethality, albuminuria, and podocyte




Fig. 1 Functional domains of the human ACTN4 protein. The actin-binding domain (ABD) consists of CH1 (amino acid 47–154) and CH2 domain (amino acid 165–268). Mutations within ACTN4 including W59R and I149del in the CH1 domain and K255E, T259I, S262P and S262F in the CH2 domain have been associated with human FSGS.

foot enfacement as seen in the Actn4 KO mice. Henderson et al. further examined the pathological characterization of both K256E and KO mice [57]. Both homozygous KI and KO mice exhibit the phenotype of collapsing glomerulopathy. Actn4 KI and KO mice did not survive past 21 and 15 weeks respectively. Homozygous KI mice and all KO mice show decreased expression of podocyte differentiation markers, including WT-1 and synaptopodin, and increased proliferation markers, including cyclin D1 and KI-67. Heterozygous Actn4 KI mice represent a more genetically faithful model for the autosomal-dominant ACTN4-mediated FSGS in humans. These mice did not develop glomerulosclerosis during the 70-week study period. However, they did exhibit focal glomerular hypertrophy and mild glomerular ultrastructural abnormalities, including mild podocyte cell body abnormalities, glomerular basement membrane (GBM) thickening and redundancy, and diffuse electron-dense aggregate accumulation. These abnormalities in heterozygous Actn4 KI mice may increase susceptibility to injury caused by other genetic or environmental stressors.

Michaud et al. generated podocyte-specific (driven by murine nephrin promoter) transgenic mice that overexpressed the K256E mutation (homologous to the human K255E mutation) [58]. Podocyte specific K256E mutant (K256E-Actn4^{Pod}) mice show heterogeneity, potentially due to variation in the expression of the transgene. The transgenic mice that had higher expression of mutant Actn4 exhibited significant albuminuria, glomerulosclerosis, and foot process enfacement at 10 weeks of age. These proteinuric transgenic mice also showed reduced expression of nephrin. Both proteinuric and non-proteinuric Actn4 transgenic mice exhibited increased average systolic BP measured by tail-cuff plethysmography. Michaud et al. also generated podocyte-specific transgenic mice overexpressing the wild-type Actn4 (WT-Actn4^{Pod}) as a control line of mice. They showed that WT-Actn4^{Pod} mice are indistinguishable from their non-transgenic littermates [59]. These mice do not develop albuminuria, glomerulosclerosis, foot process enfacement, or elevated systemic blood pressure. The authors concluded that it is the K256E Actn4 mutation, not the overexpression of Actn4, underlies the FSGS phenotype in K256E-Actn4^{Pod}.

Mechanisms by which ACTN4 mutations lead FSGS

Several studies have examined the effect of ACTN4 mutations on protein function in vitro. Weins et al. found that K255E mutant ACTN4 (full length or ABD) shows greater binding affinity to F-actin compared to WT ACTN4 based on co-sedimentation studies [60]. The addition of Ca²⁺ decreased the binding affinity of WT ACTN4 to F-actin, but not K255E ACTN4. These results

suggest that K255E mutant ACTN4 binding to F-actin is not subject to Ca²⁺ regulation in vitro. One hypothesis proposed in this study is that a conformational change occurs when mutant K255E binds to F-actin, resulting in greater binding affinity. Interestingly, the crystal structure of the ABD of mutant K255E ACTN4 in absence of actin shows the same conformation as the WT protein [52]. Perhaps, the F-actin bound form of ACTN4 adopts a different structural conformation than ACTN4 alone. Galkin et al. used cryo-electron microscopy reconstruction (relative low resolution) of F-actin cross-linked by ABD of ACTN4 to build a model. They predicted that the bound form of ACTN4 would adopt a different conformation than the unbound ACTN4 crystal structure to enable binding to F-actin [61]. Therefore, the high-resolution cryo-electron microscopy structure of F-actin cross-linked by mutant ACTN4 is needed to better explain how mutations lead to binding affinity changes of ACTN4 to F-actin, and to visualize the exact conformational changes.

Weins et al. used electron microscopy to examine the appearance of actin filaments cross-linked either by WT or K255E mutant ACTN4 in vitro [60]. They showed that WT ACTN4 crosslinks actin filaments into thick parallel bundles with defined spacing. On the other hand, mutant ACTN4 induces the formation of a disordered and entangled network of thin filament bundles. Similarly, under fluorescent microscopy, actin filaments (fluorescently labeled) cross-linked by WT ACTN4 form an evenly spaced and finely reticulated actin network. In comparison, actin filaments cross-linked by K255E mutant ACTN4 form a more coarsely reticulated network with a smaller mesh size [62]. Based on bulk rheology experiments, Ward et al. suggested that the dissociation of mutant K255E ACTN4 from actin is much slower than the WT ACTN4. Additionally, Yao et al. observed that the actin network cross-linked by K255E mutant ACTN4 is more brittle, with a lower breaking stress in comparison to networks cross-linked with WT [63]. Together, these in vitro studies reflect how mutations within ACTN4 change the intrinsic biochemical and biophysical properties of the protein.

The effects of K255E mutant ACTN4 on cellular functions have also been examined. Using immortalized lung fibroblasts and podocytes isolated from homozygous Actn4 KI mice, Weins et al. observed that mutant Actn4 aggregates with F-actin [60]. Biopsies from patients with ACTN4 mutations also show segmental weak linear, irregular granular, and punctuate appearance of ACTN4 staining surrounding the glomerular capillary wall [64]. These abnormalities could potentially be direct results of increased binding affinity to F-actin of mutant actn4, resulting in disruption of actin reorganization or

assembly. Additionally, Weins et al. also reported that two other known interacting proteins cortactin and synaptopodin were also present in the mutant Actn4/F-actin aggregates [60]. The sequestration of these binding partners, which play important roles in podocyte function, could alter the response of podocytes to environmental stressors. Michaud et al. used conditionally immortalized mouse podocytes infected with adenoviral constructs containing WT or K256E murine Actn4 to assess the functional consequence of mutations on subcellular localization, adhesion, spreading, migration, and formation of foot process-like peripheral projections [65]. They found that mutant K256E Actn4 was detected predominantly in the Triton-insoluble fraction of cellular extraction, and localizes almost exclusively along actin stress fibers. On the other hand, WT Actn4 was detected primarily in the Triton-soluble fraction of cellular extraction, localized to membrane-associated cortical actin and focal adhesions, with some expression along stress fibers. Podocytes overexpressing WT or mutant K256E Actn4 show similar adhesion to the extracellular matrix (collagen-I). However, podocytes overexpressing mutant K256E Actn4 exhibit significantly reduced ability to spread and migrate on collagen-I, and have a reduced mean number of actin-rich peripheral projections (reminiscent of podocyte foot processes in cell culture) compared to WT, perhaps all due to mutant Actn4/F-actin aggregates formation.

The sequestration of mutant ACTN4 together with F-actin in cellular aggregates can prevent ACTN4 to serve as transcriptional co-regulator. ACTN4 harbors a functional nuclear receptor interaction motif LXXLL (where L is leucine, X can be any amino acids) [41]. Khurana et al. reported that a portion of WT ACTN4 can move to the podocyte nucleus and stimulate nuclear RAR α [42] and NF- κ B [46] mediated transcription. When the LXXLL motif is mutated to LXXAA, WT ACTN4 (LXX AA) exhibits significant loss of the ability to potentiate RAR α mediated transcription. On the other hand, disease-causing mutant ACTN4, predominantly cytoplasmic, failed to translocate to the nucleus and show an inability to stimulate RAR α -mediated transcription.

Mutations within ABD of ACTN4 could lead to greater degradation of the protein in the cell [56]. Yao et al. reported that homozygous Actn4 KI mice showed markedly decreased expression of Actn4 protein in homozygous KI mice, and moderately decreased expression in heterozygous KI mice. Conditionally immortalized fibroblasts isolated from WT and homozygous K256E mice were used to compare actn4 protein synthesis and degradation rates in the cell. They found that the protein degradation rate of mutant Actn4 is much faster than WT Actn4. There is no difference in protein synthesis rates.

The greater Actn4 degradation rate could potentially explain the lower level of Actn4 protein in homozygous KI mice compared to WT mice in kidney, lung, liver and brain. Rapid degradation of Actn4 in mutant fibroblasts can be reversed by the treating of a selective proteasome inhibitor lactacystin. This result suggests that mutant Actn4 may be degraded through the ubiquitin–proteasome pathway. Interestingly, it was reported that ubiquitin C-terminal hydrolase L1 (UCHL1) is up regulated in a subset of human glomerulopathies, including primary FSGS [66]. Reed et al. intercrossed K256E-Actn4^{pod} with heterozygous UCHL1 KO mice [67]. They found that mice that are heterozygous for an Actn4 transgene but homozygous for UCHL1 KO (K256E-Actn4^{pod}/UCHL1^{-/-}) exhibited significantly ameliorated albuminuria, glomerulosclerosis, and foot process effacement at 10 weeks of age. This result suggested that preserving K256E/WT Actn4 heterodimers from proteolysis might help to maintain podocyte function.

Recently, Grgic et al. used translating ribosome affinity purification (TRAP) to isolate and compare podocyte-specific mRNA expression between heterozygous Actn4 KI mice and WT [68]. They found that among other up-regulated genes in heterozygous Actn4 KI mice, myotonic dystrophy protein kinase (Dmpk), a Rho-associated serine-threonine protein kinase, is also upregulated at the protein level in human FSGS kidney biopsies. The role of DMPK in the development of FSGS in humans has yet to be elucidated.

Conclusions

Mutations in the ACTN4 gene cause a highly penetrant, autosomal dominant form of familial FSGS in humans. Studies in Actn4 KO, Actn4 KI, and transgenic Actn4 mouse models confirm the importance of this gene in kidney function. Even though several studies have shown that ACTN4 mutations lead to biochemical, biophysical, and cellular functional changes, more research is needed to elucidate the exact pathways by which these mutations lead to podocyte injury, which may provide insights into therapeutic development. Since highly penetrant Mendelian forms of kidney disease caused by mutations in ACTN4 and other genes are rare examples where we can unequivocally identify the cause, the development of the specific therapies treating these diseases will be a proof of concept to advance individualized treatment in nephrology.

Abbreviations

ACTN4: alpha-actinin-4 gene; FSGS: familial focal segmental glomerulosclerosis; ABD: actin-binding domain; NS: nephrotic syndrome; ESRD: end stage renal disease; INF2: inverted formin 2; TRPC6: canonical transient receptor potential 6; NPHS1: nephrin; NPHS2: podocin; SRs: spectrin-like repeats; MAGI-2/S-SCAM: membrane-associated guanylate kinase inverted 2_synaptic scaffolding

molecule; IQGAP1: IQ motif-containing GTPase activating protein 1; PIP2: phosphatidylinositol 4,5-bisphosphate; PI3K: PI3 kinase; PIP3: phosphatidylinositol 3,4,5-trisphosphate; Actn4 KO: actn4 knockout; WT: wild type; Actn4 KI: actn4 K256E knock-in; GBM: glomerular basement membrane; K256E-Actn4^{pod}: podocyte specific K256E mutant; UCHL1: ubiquitin C-terminal hydrolase L1; TRAP: translating ribosome affinity purification; Dmpk: myotonic dystrophy protein kinase.

Authors' contributions

All authors participated in the writing of the review. All authors read and approved the final manuscript.

Author details

¹ Division of Nephrology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA. ² Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA.

Acknowledgement

Work in our laboratory on the topic of this review is supported by NIH grant DK59588.

Compliance with ethical guidelines

Competing interests

The authors declare that they have no competing interests.

Received: 20 April 2015 Accepted: 24 July 2015

Published online: 18 August 2015

References

- Jefferson JA, Shankland SJ. The pathogenesis of focal segmental glomerulosclerosis. *Adv Chron Kidney Dis*. 2014;21(5):408–16. doi:10.1053/j.ackd.2014.05.009.
- Swaminathan S, Leung N, Lager DJ, Melton LJ 3rd, Bergstralh EJ, Rohlinger A, et al. Changing incidence of glomerular disease in Olmsted County, Minnesota: a 30-year renal biopsy study. *Clin J Am Soc Nephrol CJASN*. 2006;1(3):483–7. doi:10.2215/CJN.00710805.
- Braden GL, Mulhern JG, O'Shea MH, Nash SV, Ucci AA Jr, Germain MJ. Changing incidence of glomerular diseases in adults. *Am J Kidney Dis Off J Natl Kidney Found*. 2000;35(5):878–83.
- Hogg R, Middleton J, Vehaskari VM. Focal segmental glomerulosclerosis—epidemiology aspects in children and adults. *Pediatr Nephrol*. 2007;22(2):183–6. doi:10.1007/s00467-006-0370-5.
- Eddy AA, Symons JM. Nephrotic syndrome in childhood. *Lancet*. 2003;362(9384):629–39. doi:10.1016/S0140-6736(03)14184-0.
- Haas M, Spargo BH, Coventry S. Increasing incidence of focal-segmental glomerulosclerosis among adult nephropathies: a 20-year renal biopsy study. *Am J Kidney Dis Off J Natl Kidney Found*. 1995;26(5):740–50.
- Kityakara C, Eggers P, Kopp JB. Twenty-one-year trend in ESRD due to focal segmental glomerulosclerosis in the United States. *Am J Kidney Dis Off J Natl Kidney Found*. 2004;44(5):815–25.
- Ichikawa I, Fogo A. Focal segmental glomerulosclerosis. *Pediatr Nephrol*. 1996;10(3):374–91.
- Bose B, Cattaran D. Toronto Glomerulonephritis R. Glomerular diseases: FSGS. *Clin J Am Soc Nephrol CJASN*. 2014;9(3):626–32. doi:10.2215/CJN.05810513.
- Korbet SM. Clinical picture and outcome of primary focal segmental glomerulosclerosis. *Nephrol Dial Transplant Off Publ Eur Dial Transplant Assoc Eur Ren Assoc*. 1999;14(Suppl 3):68–73.
- Korbet SM. Treatment of primary FSGS in adults. *J Am Soc Nephrol JASN*. 2012;23(11):1769–76. doi:10.1681/ASN.2012040389.
- Kaplan JM, Kim SH, North KN, Renne H, Correia LA, Tong HQ, et al. Mutations in ACTN4, encoding alpha-actinin-4, cause familial focal segmental glomerulosclerosis. *Nat Genet*. 2000;24(3):251–6. doi:10.1038/73456.
- Brown EJ, Schlondorff JS, Becker DJ, Tsukaguchi H, Tonna SJ, Uscinski AL, et al. Mutations in the formin gene INF2 cause focal segmental glomerulosclerosis. *Nat Genet*. 2010;42(1):72–6. doi:10.1038/ng.505.
- Reiser J, Polu KR, Moller CC, Kenlan P, Altintas MM, Wei C, et al. TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal function. *Nat Genet*. 2005;37(7):739–44. doi:10.1038/ng1592.
- Winn MP, Conlon PJ, Lynn KL, Farrington MK, Creazzo T, Hawkins AF, et al. A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis. *Science*. 2005;308(5729):1801–4. doi:10.1126/science.1106215.
- Kestila M, Lenkkeri U, Mannikko M, Lamerdin J, McCready P, Putaala H, et al. Positionally cloned gene for a novel glomerular protein—nephrin—is mutated in congenital nephrotic syndrome. *Mol Cell*. 1998;1(4):575–82.
- Boute N, Gribouval O, Roselli S, Benessy F, Lee H, Fuchshuber A, et al. NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome. *Nat Genet*. 2000;24(4):349–54. doi:10.1038/74166.
- Otey CA, Carpen O. Alpha-actinin revisited: a fresh look at an old player. *Cell Motil Cytoskelet*. 2004;58(2):104–11. doi:10.1002/cm.20007.
- Beggs AH, Byers TJ, Knoll JH, Boyce FM, Bruns GA, Kunkel LM. Cloning and characterization of two human skeletal muscle alpha-actinin genes located on chromosomes 1 and 11. *J Biol Chem*. 1992;267(13):9281–8.
- BurrIDGE K, Feramisco JR. Non-muscle alpha actinins are calcium-sensitive actin-binding proteins. *Nature*. 1981;294(5841):565–7.
- Nikolopoulos SN, Spengler BA, Kisselbach K, Evans AE, Biedler JL, Ross RA. The human non-muscle alpha-actinin protein encoded by the ACTN4 gene suppresses tumorigenicity of human neuroblastoma cells. *Oncogene*. 2000;19(3):380–6. doi:10.1038/sj.onc.1203310.
- Kunishima S, Okuno Y, Yoshida K, Shiraishi Y, Sanada M, Muramatsu H, et al. ACTN1 mutations cause congenital macrothrombocytopenia. *Am J Hum Genet*. 2013;92(3):431–8. doi:10.1016/j.ajhg.2013.01.015.
- Chiu C, Bagnall RD, Ingles J, Yeates L, Kennerson M, Donald JA, et al. Mutations in alpha-actinin-2 cause hypertrophic cardiomyopathy: a genome-wide analysis. *J Am Coll Cardiol*. 2010;55(11):1127–35. doi:10.1016/j.jacc.2009.11.016.
- North KN, Yang N, Wattanasirichaigoon D, Mills M, Easteal S, Beggs AH. A common nonsense mutation results in alpha-actinin-3 deficiency in the general population. *Nat Genet*. 1999;21(4):353–4. doi:10.1038/7675.
- Yang N, MacArthur DG, Gulbin JP, Hahn AG, Beggs AH, Easteal S, et al. ACTN3 genotype is associated with human elite athletic performance. *Am J Hum Genet*. 2003;73(3):627–31. doi:10.1086/377590.
- Pavalko FM, Otey CA, Simon KO, BurrIDGE K. Alpha-actinin: a direct link between actin and integrins. *Biochem Soc Trans*. 1991;19(4):1065–9.
- Otey CA, Vasquez GB, BurrIDGE K, Erickson BW. Mapping of the alpha-actinin binding site within the beta 1 integrin cytoplasmic domain. *J Biol Chem*. 1993;268(28):21193–7.
- Bois PR, Borgon RA, Vonrhein C, Izard T. Structural dynamics of alpha-actinin-vinculin interactions. *Mol Cell Biol*. 2005;25(14):6112–22. doi:10.1128/MCB.25.14.6112-6122.2005.
- Kroemker M, Rudiger AH, Jockusch BM, Rudiger M. Intramolecular interactions in vinculin control alpha-actinin binding to the vinculin head. *FEBS Lett*. 1994;355(3):259–62.
- Li B, Trueb B. Analysis of the alpha-actinin/zyxin interaction. *J Biol Chem*. 2001;276(36):33328–35. doi:10.1074/jbc.M100789200.
- Has C, Herz C, Zimina E, Qu HY, He Y, Zhang ZG, et al. Kindlin-1 is required for RhoGTPase-mediated lamellipodia formation in keratinocytes. *Am J Pathol*. 2009;175(4):1442–52. doi:10.2353/ajpath.2009.090203.
- Reiser J, Kriz W, Kretzler M, Mundel P. The glomerular slit diaphragm is a modified adherens junction. *J Am Soc Nephrol JASN*. 2000;11(1):1–8.
- Nieset JE, Redfield AR, Jin F, Knudsen KA, Johnson KR, Wheelock MJ. Characterization of the interactions of alpha-catenin with alpha-actinin and beta-catenin/plakoglobin. *J Cell Sci*. 1997;110(Pt 8):1013–22.
- Lehtonen S, Ryan JJ, Kudlicka K, Iino N, Zhou H, Farquhar MG. Cell junction-associated proteins IQGAP1, MAGI-2, CASK, spectrins, and alpha-actinin are components of the nephrin multiprotein complex. *Proc Natl Acad Sci USA*. 2005;102(28):9814–9. doi:10.1073/pnas.0504166102.
- Fraleigh TS, Tran TC, Corgan AM, Nash CA, Hao J, Critchley DR, et al. Phosphoinositide binding inhibits alpha-actinin bundling activity. *J Biol Chem*. 2003;278(26):24039–45. doi:10.1074/jbc.M213288200.
- Fraleigh TS, Pereira CB, Tran TC, Singleton C, Greenwood JA. Phosphoinositide binding regulates alpha-actinin dynamics: mechanism for modulating cytoskeletal remodeling. *J Biol Chem*. 2005;280(15):15479–82. doi:10.1074/jbc.M500631200.
- Ding Z, Liang J, Lu Y, Yu Q, Songyang Z, Lin SY, et al. A retrovirus-based protein complementation assay screen reveals functional AKT1-binding partners. *Proc Natl Acad Sci USA*. 2006;103(41):15014–9. doi:10.1073/pnas.0606917103.

38. Sprague CR, Fraley TS, Jang HS, Lal S, Greenwood JA. Phosphoinositide binding to the substrate regulates susceptibility to proteolysis by calpain. *J Biol Chem*. 2008;283(14):9217–23. doi:10.1074/jbc.M707436200.
39. Honda K, Yamada T, Endo R, Ino Y, Gotoh M, Tsuda H, et al. Actinin-4, a novel actin-bundling protein associated with cell motility and cancer invasion. *J Cell Biol*. 1998;140(6):1383–93.
40. Khurana S, Chakraborty S, Zhao X, Liu Y, Guan D, Lam M, et al. Identification of a novel LXXLL motif in alpha-actinin 4-spliced isoform that is critical for its interaction with estrogen receptor alpha and co-activators. *J Biol Chem*. 2012;287(42):35418–29. doi:10.1074/jbc.M112.401364.
41. Khurana S, Chakraborty S, Cheng X, Su YT, Kao HY. The actin-binding protein, actinin alpha 4 (ACTN4), is a nuclear receptor coactivator that promotes proliferation of MCF-7 breast cancer cells. *J Biol Chem*. 2011;286(3):1850–9. doi:10.1074/jbc.M110.162107.
42. Khurana S, Chakraborty S, Lam M, Liu Y, Su YT, Zhao X, et al. Familial focal segmental glomerulosclerosis (FSGS)-linked alpha-actinin 4 (ACTN4) protein mutants lose ability to activate transcription by nuclear hormone receptors. *J Biol Chem*. 2012;287(15):12027–35. doi:10.1074/jbc.M112.345421.
43. Chakraborty S, Reineke EL, Lam M, Li X, Liu Y, Gao C, et al. Alpha-actinin 4 potentiates myocyte enhancer factor-2 transcription activity by antagonizing histone deacetylase 7. *J Biol Chem*. 2006;281(46):35070–80. doi:10.1074/jbc.M602474200.
44. An HT, Kim J, Yoo S, Ko J. Small leucine zipper protein (sLZIP) negatively regulates skeletal muscle differentiation via interaction with alpha-actinin-4. *J Biol Chem*. 2014;289(8):4969–79. doi:10.1074/jbc.M113.515395.
45. Jasavala R, Martinez H, Thumar J, Andaya A, Gingras AC, Eng JK, et al. Identification of putative androgen receptor interaction protein modules: cytoskeleton and endosomes modulate androgen receptor signaling in prostate cancer cells. *Mol Cell Proteom MCP*. 2007;6(2):252–71. doi:10.1074/mcp.M600169-MCP200.
46. Zhao X, Hsu KS, Lim JH, Bruggeman LA, Kao HY. alpha-Actinin 4 potentiates nuclear factor kappa-light-chain-enhancer of activated B-cell (NF-kappaB) activity in podocytes independent of its cytoplasmic actin binding function. *J Biol Chem*. 2015;290(1):338–49. doi:10.1074/jbc.M114.597260.
47. Smoyer WE, Mundel P, Gupta A, Welsh MJ. Podocyte alpha-actinin induction precedes foot process effacement in experimental nephrotic syndrome. *Am J Physiol*. 1997;273(1 Pt 2):F150–7.
48. Kurihara H, Anderson JM, Farquhar MG. Increased Tyr phosphorylation of ZO-1 during modification of tight junctions between glomerular foot processes. *Am J Physiol*. 1995;268(3 Pt 2):F514–24.
49. Weins A, Kenlan P, Herbert S, Le TC, Villegas I, Kaplan BS, et al. Mutational and biological analysis of alpha-actinin-4 in focal segmental glomerulosclerosis. *J Am Soc Nephrol JASN*. 2005;16(12):3694–701. doi:10.1681/ASN.2005070706.
50. Choi HJ, Lee BH, Cho HY, Moon KC, Ha IS, Nagata M, et al. Familial focal segmental glomerulosclerosis associated with an ACTN4 mutation and paternal germline mosaicism. *Am J Kidney Dis Off J Natl Kidney Found*. 2008;51(5):834–8. doi:10.1053/j.ajkd.2008.01.018.
51. Franzot G, Sjoblom B, Gautel M, Djinovic Carugo K. The crystal structure of the actin binding domain from alpha-actinin in its closed conformation: structural insight into phospholipid regulation of alpha-actinin. *J Mol Biol*. 2005;348(1):151–65. doi:10.1016/j.jmb.2005.01.002.
52. Lee SH, Weins A, Hayes DB, Pollak MR, Dominguez R. Crystal structure of the actin-binding domain of alpha-actinin-4 Lys255Glu mutant implicated in focal segmental glomerulosclerosis. *J Mol Biol*. 2008;376(2):317–24. doi:10.1016/j.jmb.2007.11.084.
53. Kos CH, Le TC, Sinha S, Henderson JM, Kim SH, Sugimoto H, et al. Mice deficient in alpha-actinin-4 have severe glomerular disease. *J Clin Invest*. 2003;111(11):1683–90. doi:10.1172/JCI17988.
54. Dandapani SV, Sugimoto H, Matthews BD, Kolb RJ, Sinha S, Gerszten RE, et al. Alpha-actinin-4 is required for normal podocyte adhesion. *J Biol Chem*. 2007;282(1):467–77. doi:10.1074/jbc.M605024200.
55. Liu Z, Blattner SM, Tu Y, Tisherman R, Wang JH, Rastaldi MP, et al. Alpha-actinin-4 and CLP36 protein deficiencies contribute to podocyte defects in multiple human glomerulopathies. *J Biol Chem*. 2011;286(35):30795–805. doi:10.1074/jbc.M111.255984.
56. Yao J, Le TC, Kos CH, Henderson JM, Allen PG, Denker BM, et al. Alpha-actinin-4-mediated FSGS: an inherited kidney disease caused by an aggregated and rapidly degraded cytoskeletal protein. *PLoS Biol*. 2004;2(6):e167. doi:10.1371/journal.pbio.0020167.
57. Henderson JM, Al-Waheeb S, Weins A, Dandapani SV, Pollak MR. Mice with altered alpha-actinin-4 expression have distinct morphologic patterns of glomerular disease. *Kidney Int*. 2008;73(6):741–50. doi:10.1038/sj.ki.5002751.
58. Michaud JL, Lemieux LI, Dube M, Vanderhyden BC, Robertson SJ, Kennedy CR. Focal and segmental glomerulosclerosis in mice with podocyte-specific expression of mutant alpha-actinin-4. *J Am Soc Nephrol JASN*. 2003;14(5):1200–11.
59. Michaud JL, Stitt-Cavanaugh E, Endlich N, Endlich K, De Repentigny Y, Kothary R, et al. Mice with podocyte-specific overexpression of wild type alpha-actinin-4 are healthy controls for K256E-alpha-actinin-4 mutant transgenic mice. *Transgenic Res*. 2010;19(2):285–9. doi:10.1007/s11248-009-9305-9.
60. Weins A, Schlondorff JS, Nakamura F, Denker BM, Hartwig JH, Stoszel TP, et al. Disease-associated mutant alpha-actinin-4 reveals a mechanism for regulating its F-actin-binding affinity. *Proc Natl Acad Sci USA*. 2007;104(41):16080–5. doi:10.1073/pnas.0702451104.
61. Galkin VE, Orlova A, Salmazo A, Djinovic-Carugo K, Egelman EH. Opening of tandem calponin homology domains regulates their affinity for F-actin. *Nat Struct Mol Biol*. 2010;17(5):614–6. doi:10.1038/nsmb.1789.
62. Ward SM, Weins A, Pollak MR, Weitz DA. Dynamic viscoelasticity of actin cross-linked with wild-type and disease-causing mutant alpha-actinin-4. *Biophys J*. 2008;95(10):4915–23. doi:10.1529/biophysj.108.131722.
63. Yao NY, Becker DJ, Broedersz CP, Depken M, Mackintosh FC, Pollak MR, et al. Nonlinear viscoelasticity of actin transiently cross-linked with mutant alpha-actinin-4. *J Mol Biol*. 2011;411(5):1062–71. doi:10.1016/j.jmb.2011.06.049.
64. Henderson JM, Alexander MP, Pollak MR. Patients with ACTN4 mutations demonstrate distinctive features of glomerular injury. *J Am Soc Nephrol JASN*. 2009;20(5):961–8. doi:10.1681/ASN.2008060613.
65. Michaud JL, Chaisson KM, Parks RJ, Kennedy CR. FSGS-associated alpha-actinin-4 (K256E) impairs cytoskeletal dynamics in podocytes. *Kidney Int*. 2006;70(6):1054–61. doi:10.1038/sj.ki.5001665.
66. Meyer-Schwesinger C, Meyer TN, Munster S, Klug P, Saleem M, Helmchen U, et al. A new role for the neuronal ubiquitin C-terminal hydrolase-L1 (UCH-L1) in podocyte process formation and podocyte injury in human glomerulopathies. *J Pathol*. 2009;217(3):452–64. doi:10.1002/path.2446.
67. Read NC, Gutsol A, Holterman CE, Carter A, Coulombe J, Gray DA, et al. Ubiquitin C-terminal hydrolase L1 deletion ameliorates glomerular injury in mice with ACTN4-associated focal segmental glomerulosclerosis. *Biochim Biophys Acta*. 2014;1842(7):1028–40. doi:10.1016/j.bbdis.2014.03.009.
68. Grdic I, Hofmeister AF, Genovese G, Bernhardt AJ, Sun H, Maarouf OH, et al. Discovery of new glomerular disease-relevant genes by translational profiling of podocytes in vivo. *Kidney Int*. 2014;86(6):1116–29. doi:10.1038/ki.2014.204.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

